SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending as traders discuss its potential for a short squeeze and speculate on price movements, with some expressing concerns about it being a pump and dump. The stock's low float and recent volatility are key points of discussion, with community members comparing it to other robotics plays. Some traders are also eyeing related tickers, anticipating similar potential moves.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to discussions around a potential short squeeze and high volatility, fueled by the company's recent activity and a relatively small float. Community members are debating fair value and if it is worth accumulating, and some traders are highlighting technical indicators. The company is a clinical-stage biopharmaceutical firm focused on developing innovative oncology radiopharmaceuticals.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending amid discussions of a potential short squeeze, fueled by its low float and recent price surges, leading to multiple trading halts. The community is actively debating entry and exit points, comparing it to other low-float runners, and anticipating a possible breakout if it surpasses key resistance levels. Some traders caution about potential dilution given the company's structure.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending, fueled by Wedbush's reaffirmed bullish outlook and robotaxi optimism, despite concerns about valuation and declining EV sales; the community is buzzing about the potential for new all-time highs and debates the impact of AI and SpaceX on the stock, with both bulls and bears digging in.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending as the community discusses the potential for a short squeeze and the impact of preliminary data showing an 80% reduction in breast cancer recurrence rates. Community members are debating the significance of the news, speculating about a potential buyout, and analyzing short interest data. The stock is seen as a biotech microcap with a history of explosive moves, making it a high-risk, high-reward play.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending downwards, sparking debates about its viability and potential for a delisting pump. Community members are expressing frustration with its performance relative to Bitcoin and other altcoins, with some labeling it a scam due to perceived lack of utility and the performance of the Janction token. Despite the negative sentiment, some bulls remain hopeful, citing ongoing development, partnerships, and the potential for a turnaround in 2026.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow's stock is trending amid reports of a potential acquisition of cybersecurity firm Armis, sparking debate about the deal's price tag and strategic fit. While some investors are wary of the cost and integration risks, analysts remain optimistic about the long-term upside of strengthening ServiceNow's platform with cybersecurity capabilities. The community is weighing the short-term volatility against the potential for long-term gains in the cybersecurity space.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending after receiving FDA Fast Track designation for its AlloNK therapy in refractory rheumatoid arthritis, a significant step for its clinical development. The community is discussing the potential impact on the autoimmune market and the possibility of future data readouts and clinical responses. Bullish sentiment is fueled by analyst upgrades and price target increases, though some caution against potential dilution and profit-taking.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation surrounding potential marijuana rescheduling, driven by rumors of an upcoming announcement and a possible executive order. Community discussions revolve around the potential impact on the cannabis sector, tax implications, and Tilray's future market position, with some traders anticipating a significant short squeeze if the rescheduling occurs.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is trending after reporting positive Phase 2 trial results for its CAR-T cell therapy in stiff person syndrome, leading to plans for a BLA submission in 1H 2026.  The community is discussing the potential of miv-cel to become the first approved therapy for SPS and the first CAR T treatment for autoimmune disease, while also highlighting the company's strong financial position and acquisition potential. Some are concerned about the niche market affecting sales and stability, while others are excited about the possibility of a double-digit valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ATOM My short thesis from earlier in the week is even stronger than before. The float is tighter and the shorting has continued in my opinion. Every shareholder I have talked to this week has added shares taking advantage of the ATM non-event to add. The LD Micro conference provided the business case and potential royalty generation the company is capable of in the future. At 1% of the market they would generate $150m in royalties and over $6/share in earnings. Royalties are 100% profit margins and fixed costs for this company are less than $20m/year. At 10% penetration the royalties are 1.5 BILLION/year. For a product that  greatly improves all electronic parts performance thats a low price to pay. Keep in mind if the company makes that the fab makes 4x time that so a real win win and why wouldn&#39;t they license. Here is the updated material. 

https://joesstockreports.wordpress.com/2020/08/30/atomeraatom-epic-short-squeeze-possible-with-multiple-catalysts-on-the-horizon/

ReaITruth

Daniel

Benph

Jwa68

Mr. Long

Updated 9/3/20. Short attack continues. The company filed to allow ATM share sales of up to $25m in new shares. This filing does not mean any shares will necessarily be sold in the future. At current price that would be around 2m shares which would only increase the outstanding shares to around 22 million.

joesstockreports

Atomera(ATOM): Epic short squeeze possible with multiple catalysts on the horizon!

StockTwits For Android 

Atomera Inc

 My short thesis from earlier in the week is even stronger than before. The float is tighter and the shorting has continued in my opinion. Every shareholder I have talked to this week has added shares taking advantage of the ATM non-event to add. The LD Micro conference provided the business case and potential royalty generation the company is capable of in the future. At 1% of the market they would generate $150m in royalties and over $6/share in earnings. Royalties are 100% profit margins and fixed costs for this company are less than $20m/year. At 10% penetration the royalties are 1.5 BILLION/year. For a product that  greatly improves all electronic parts performance thats a low price to pay. Keep in mind if the company makes that the fab makes 4x time that so a real win win and why wouldn't they license. Here is the updated material. 



@microcapspeculator oops sorry didnt see you post about the ATM stuff already!

 oops sorry didnt see you post about the ATM stuff already!

@microcapspeculator i would assume 1% royalty license would be the bare minimum if ever a customer negotiated down to that level. But even at 1%, the potential revenue is still significant!

 i would assume 1% royalty license would be the bare minimum if ever a customer negotiated down to that level. But even at 1%, the potential revenue is still significant!

@Benph @microcapspeculator I think if they ever use it at a much higher price they might open an office in another country. Having support locally may eventually be needed.  Wouldn&#39;t that be amazing if they announced that in the future? It seems like a natural. I mean where might these new hires work out of?

 I think if they ever use it at a much higher price they might open an office in another country. Having support locally may eventually be needed.  Wouldn't that be amazing if they announced that in the future? It seems like a natural. I mean where might these new hires work out of?

@Benph @microcapspeculator Sorry for the confusion. That&#39;s market penetration and uses the 2% royalty rate. The numbers I have seen are 240m wafers per year. 1% would be 2.4m wafers x$68/wafer royalty. Or roughly $150m in royalties if they capture just 1% of the market. At 10% of market it&#39;s billions.

 Sorry for the confusion. That's market penetration and uses the 2% royalty rate. The numbers I have seen are 240m wafers per year. 1% would be 2.4m wafers x$68/wafer royalty. Or roughly $150m in royalties if they capture just 1% of the market. At 10% of market it's billions.

@microcapspeculator @Benph @microcapspeculator right, if there is one lesson learned from the pandemic, it is that they need overseas staff to serve international customers. They will definitely need extra cash in the future for expansion and that ATM is a buffer in case they need expansion within the year..

 right, if there is one lesson learned from the pandemic, it is that they need overseas staff to serve international customers. They will definitely need extra cash in the future for expansion and that ATM is a buffer in case they need expansion within the year..

@microcapspeculator @Benph @microcapspeculator no need to be sorry, i was the one who got confused with the 1% thing:) So its market penetration. With that $150M in pure profit, the stock would be trading around 150 to 200..!

 no need to be sorry, i was the one who got confused with the 1% thing:) So its market penetration. With that $150M in pure profit, the stock would be trading around 150 to 200..!

@Benph @Benph @microcapspeculator Yep. We never had the business slide before but licensing has to make sense to adopt someone else&#39;s technology. This is going to be widely adopted.

 Yep. We never had the business slide before but licensing has to make sense to adopt someone else's technology. This is going to be widely adopted.